A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-Met co-expressing metastatic pancreatic adenocarcinoma
This study is being done to test if treatment with both cabozantinib and erlotinib has an effect on pancreatic cancer.
The purpose of this study is to look at a novel combination of targeted agents in a biomarker-selected population of patients with pancreatic cancer.
Participants will not be paid for their participation.
- IRB Number: 1705697788 (IUSCC-0597)
- Research Study Identifier: TX8222
- Principal Investigator: Patrick Loehrer, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required